Promising drug development efforts may frequently fail due to unintended adverse reactions.
Several methods have been developed to analyze such data, aiming to improve …

The development of monoclonal antibodies has dramatically changed the outcome of
patients with non-Hodgkin's lymphoma (NHL), the most common hematological malignancy …

Primary T cell has been transformed into a cell‐based delivery platform that synthesizes
complex biologics at the disease site with spatiotemporal resolution. This broadly applicable …

Infection with SARS-CoV-2 coronavirus causes systemic, multi-faceted COVID-19 disease.
However, knowledge connecting its intricate clinical manifestations with molecular …

Background Several studies have examined the drug–drug interaction patterns in different
patient populations and treatment settings; however, there is a need, particularly in the field …

Since early 2020 the COVID-19 pandemic has paralyzed the world, resulting in more than
half a billion infections and over 6 million deaths within a 28-month period. Knowledge …

Immunotherapy became a key pillar of cancer therapeutics with the approvals of ipilimumab,
nivolumab, and pembrolizumab, which inhibit either cytotoxic T‐lymphocyte antigen‐4 …

Adverse drug reactions (ADRs) of targeted therapy drugs (TTDs) are frequently unexpected
and long‐term toxicities detract from exceptional efficacy of new TTDs. In this proof‐of …

Background: Medication errors, prescribing errors, adverse drug events (ADEs), and side
effects are critical aspects of drug-related patient safety. These errors can occur at various …

Immune checkpoint inhibition represents an important therapeutic option for advanced
melanoma patients. Results from clinical studies have shown that treatment with the PD-1 …